Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
Teva Nailed With S&P Downgrade - TheStreet
Why Teva's Stock Could Crash Another 50% | BioSpace
Israeli company Teva Pharmaceutical stocks drop nearly 18% - The Jerusalem Post
S&P Global Ratings affirms Teva Pharmaceutical Industries at "BB-" (Local Currency LT credit rating); outlook stable
CSRWire - Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
S&P cuts Teva's rating on rising litigation risks
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook Jerusalem, Israel, December 13, 2012 - Teva Pharmaceutical Indu
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Idea of the Week: Teva Pharmaceutical—The Top Leader in Generic Drugs | Bondsupermart
Moody's upgrades Teva's rating outlook - גלובס
Teva's Working With Evercore to Review Debt Options - Bloomberg
Healthcare companies face pricing pressure, regulatory wild cards in 2018: S&P | S&P Global Market Intelligence
Teva to Repay Due Loans with Junk Bond Private Offering | Ctech
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Sees Significant Decrease in Short Interest - MarketBeat
Teva's Bonds Rally on News of $4.35bn US Opioid Crisis Settlement
Moody's Downgrades Teva Bond Rating to “Junk” | Ctech
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
S&P Downgrades Teva, Pushing Credit Rating Further Into Junk Territory - Business - Haaretz.com
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
